Author

Jason A. Gross

Observed name: Jason A Gross

Institution: HLS Therapeutics (Canada)

Observed institution: HLS Therapeutics (Canada)

ORCID: 0009-0000-9696-8267

Observed ORCID: 0009-0000-9696-8267

OpenAlex ID: A5042944136

Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: A randomized, 4-treatment, crossover study

2013 · Guy F. Webster, James J. Leyden, et al. · Journal of the American Academy of Dermatology · 54

Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.

2014 · Guy F Webster, James J Leyden, et al. · PubMed · 38

Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

2023 · Carlos De las Cuevas, Emilio J. Sanz, et al. · Schizophrenia Research · 22

Microbial Challenge of Stable Compounded Clozapine Suspensions in Plastic Bottles.

2025 · Jessica Berzy, Hanif Sachedina, et al. · PubMed

Works count: 4

Citation count: 114

H-index: 3

I10-index: 3